AlphaRx Presents Positive Data From Preclinical Studies of Cystic Fibrosis Drug
Posted on: Thursday, 5 June 2008, 09:01 CDT
AlphaRx has announced positive pre-clinical data on Zysolin, a Tobramycin compound encapsulated in the company's nano drug delivery platform intended for the treatment of cystic fibrosis and an adjunctive treatment of Gram-negative pneumonia in intubated and mechanically-ventilated patients.
In the recent animal study, the therapeutic efficacy of Zysolin was investigated in a mouse model of Pseudomonas aeruginosa pneumonia. In this acute model, pneumonia developed rapidly, resulting in a high mortality rate, no mice survived after 24 hours of infection without treatment.
Mice treated with Zysolin showed significantly better efficacy than Tobramycin, achieving 60% survival rate compared to 40% in the Tobramycin treatment group. An increase of survival by 50% or more, relative to vehicle control, indicates significant anti-microbial effect. The Tobramycin treatment group did not meet the study's end point.
Source: Datamonitor
Related Articles
- Study Finds More Effective Treatment for Pneumonia Following Influenza
- Study Finds More Effective Treatment for Pneumonia Following Influenza
- Rep: Mac Responding Well to Treatment
- Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
- Ford's Hospital Stay Extended As He Battles Pneumonia
- Ex-President Gerald Ford Hospitalized for Pneumonia
- Former President Gerald Ford Hospitalized
- Winter Taking a Toll on Pakistanis
- Harvard Study Ranks OKC No. 1 Nationally in Treating Pneumonia
- Brooklyn, N.Y., Hospitals Fail Federal Checkup
 |
 |
User Comments (0)
RSS Feeds